Dyspepsia Prevention — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for dyspepsia prevention. 5 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
5
Active US patents
73/100
Avg vulnerability
—
Annual revenue covered

Originators in Dyspepsia Prevention

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Yamanouchi/Merck) 5 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating dyspepsia prevention. Each bar = one year. Y-axis scaled to peak year (5 patents).

5
26

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pepcid
famotidine
 Generic (originally Yamanouchi/Merck) 5 73 — 2026-07-18

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8067451 Pepcid method of use 85 2026-07-18
8501228 Pepcid method of use 85 2026-07-18
8449910 Pepcid formulation 65 2026-07-18
8309127 Pepcid formulation 65 2026-07-18
8318202 Pepcid formulation 65 2026-07-18

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8449910 Pepcid formulation 65 2026-07-18
8309127 Pepcid formulation 65 2026-07-18
8318202 Pepcid formulation 65 2026-07-18
8067451 Pepcid method of use 85 2026-07-18
8501228 Pepcid method of use 85 2026-07-18

Related